GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » PB Ratio

DiaMedica Therapeutics (DiaMedica Therapeutics) PB Ratio

: 1.85 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), DiaMedica Therapeutics's share price is $2.49. DiaMedica Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.35. Hence, DiaMedica Therapeutics's PB Ratio of today is 1.85.

The historical rank and industry rank for DiaMedica Therapeutics's PB Ratio or its related term are showing as below:

DMAC' s PB Ratio Range Over the Past 10 Years
Min: 1.16   Med: 3.15   Max: 51.46
Current: 1.84

During the past 13 years, DiaMedica Therapeutics's highest PB Ratio was 51.46. The lowest was 1.16. And the median was 3.15.

DMAC's PB Ratio is ranked better than
60.21% of 1312 companies
in the Biotechnology industry
Industry Median: 2.385 vs DMAC: 1.84

During the past 12 months, DiaMedica Therapeutics's average Book Value Per Share Growth Rate was 11.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 5.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DiaMedica Therapeutics was 123.10% per year. The lowest was -50.70% per year. And the median was 2.20% per year.

Back to Basics: PB Ratio


DiaMedica Therapeutics PB Ratio Historical Data

The historical data trend for DiaMedica Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.65 7.31 2.24 1.31 2.11

DiaMedica Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.50 2.74 1.76 2.11

Competitive Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's PB Ratio falls into.



DiaMedica Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

DiaMedica Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.49/1.345
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


DiaMedica Therapeutics  (NAS:DMAC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


DiaMedica Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305

DiaMedica Therapeutics (DiaMedica Therapeutics) Headlines